Stock Insights: Achillion Pharmaceuticals, DG FastChannel, Tempur Pedic, Iron Mountain, Nasdaq OMX June 7th

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Baird said any potential weakness in Achillion following the announcement of its Chief Medical Officer should be bought citing the company;s catalyst rich period. The firm is also confident in the chief Scientific Officer’s ability to assume the CMO’s duties and do not see any disruption. Shares are Outperform rated with a $15 price target.

DG FastChannel, Inc. (NASDAQ:DGIT): Piper Jaffray believes a potential formal bid for Digital Generation from a private or strategic buyer other than Extreme Reach, whose bid was reportedly rejected, is unlikely to materialize at current levels. The firm reiterates an Underweight rating on Digital Generation citing continued declining fundamentals in both the company’s TV and Internet segments.

Tempur Pedic International Inc. (NYSE:TPX): Stifel Nicolaus reduced its target on Tempur-Pedic after the company lowered its FY12 EPS guidance due to a sharp drop in May U.S. sales. However, the firm thinks that yesterday’s sell-off was somewhat overdone and it maintains a Buy rating on the shares.

Iron Mountain Inc. (NYSE:IRM): Piper Jaffray raised its price target and views the risk/reward on shares of Iron Mountain as attractive following the company’s plans to convert to a REIT. Piper reiterates an Overweight rating on the stock.

Nasdaq OMX Group Inc. (NASDAQ:NDAQ): After NASDAQ (NASDAQ:NDAQ) announced that it would allocate $40M to compensate customers who lost money as a result of technical problems with the Facebook (NASDAQ:FB) IPO, Stifel believes that the sum is less than feared and “highly manageable.” The firm thinks that the stock’s worst difficulties are behind it and it maintains a Buy rating on the shares.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.